KDR and neoplasm: Targeting tumor angiogenesis has been approached through monoclonal antibodies that block VEGF-VEGFR binding15–17, and several drugs that block the VEGF/VEGFR pathway, such as bevacizumab and ramucirumab, have been approved by the FDA for treatment of common solid tumors18–21.